You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 14, 2024

Chemocentryx Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for CHEMOCENTRYX, and when can generic versions of CHEMOCENTRYX drugs launch?

CHEMOCENTRYX has one approved drug.

There are four US patents protecting CHEMOCENTRYX drugs.

There are ninety patent family members on CHEMOCENTRYX drugs in thirty-seven countries and ten supplementary protection certificates in ten countries.

Summary for Chemocentryx
International Patents:90
US Patents:4
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Chemocentryx

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chemocentryx TAVNEOS avacopan CAPSULE;ORAL 214487-001 Oct 7, 2021 RX Yes Yes 8,906,938 ⤷  Sign Up Y Y ⤷  Sign Up
Chemocentryx TAVNEOS avacopan CAPSULE;ORAL 214487-001 Oct 7, 2021 RX Yes Yes 8,445,515 ⤷  Sign Up Y Y ⤷  Sign Up
Chemocentryx TAVNEOS avacopan CAPSULE;ORAL 214487-001 Oct 7, 2021 RX Yes Yes 11,951,214 ⤷  Sign Up Y ⤷  Sign Up
Chemocentryx TAVNEOS avacopan CAPSULE;ORAL 214487-001 Oct 7, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up
Chemocentryx TAVNEOS avacopan CAPSULE;ORAL 214487-001 Oct 7, 2021 RX Yes Yes 11,603,356 ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Chemocentryx Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2381778 2022C/518 Belgium ⤷  Sign Up PRODUCT NAME: TAVNEOS - AVACOPAN ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/21/1605 20220119
2381778 C202230016 Spain ⤷  Sign Up PRODUCT NAME: AVACOPAN Y SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/21/1605; DATE OF AUTHORISATION: 20220111; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1605; DATE OF FIRST AUTHORISATION IN EEA: 20220111
2381778 LUC00258 Luxembourg ⤷  Sign Up PRODUCT NAME: AVACOPAN ET LES SELS PHARMACEUTIQUEMENT ACCEPTABLES QUI EN DERIVENT; AUTHORISATION NUMBER AND DATE: EU/1/21/1605 20220119
2381778 22C1020 France ⤷  Sign Up PRODUCT NAME: AVACOPAN ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/21/1605 20220119
2381778 17/2022 Austria ⤷  Sign Up PRODUCT NAME: AVACOPAN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; REGISTRATION NO/DATE: EU/1/21/1605 (MITTEILUNG) 20220119
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.